GlassScriptPhysician profile
Jason B Brayer
NPI 1427285451
$61,834.47
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $11K · 2021: $6,908 · 2022: $30K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $23,326.73 | 2019-2022 | |
| Glaxosmithkline, LLC. | $15,754.69 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $8,155.36 | 2019-2022 | |
| Karyopharm Therapeutics INC. | $7,076.25 | 2022 | |
| Amgen INC. | $6,128.08 | 2019-2022 | |
| Celgene Corporation | $536.88 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $228.80 | 2022 | |
| Regeneron Pharmaceuticals, INC. | $152.43 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $141.36 | 2022 | |
| Abbvie INC. | $138.05 | 2021-2022 | |
| Stemline Therapeutics INC. | $126.51 | 2019 | |
| Beigene USA, INC. | $69.33 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$6,066.65 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Brayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.